You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.
Researchers have demonstrated that they can detect more miRNAs, as well as other small RNA molecules, by sequencing these samples rather than using microarrays.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
In Nature this week: genetic history of early European farmers, and more.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.
Using two guide RNAs to excise chunks of the genome, an international team identified lncRNAs essential and inhibitory to human cancer cell line proliferation.
By modifying a library construction method, researchers were able to analyze tiny amounts of small RNAs.
Researchers have identified hundreds of new and known microRNAs in the domestic dog genome, a finding that could contribute to disease research.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.